Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

Unity’s restructuring comes along with 36-week results from its phase 2b Aspire trial that weighed its investigational eye treatment UBX1325 against Regeneron’s blockbuster Eylea in patients ...

Credit: mrinalpal / Shutterstock.com. Indian commercial vehicle manufacturer Tata Motors reported a 6.15% decline in total sales, including both domestic and international markets, with 72,753 ...

Tata, despite a YoY sales decline, has pipped Hyundai to take the third place, selling 45,199 units in the domestic market, followed by Hyundai in third, with 44,374 units sold in India.

Regeneron Pharmaceuticals ... affordability challenges. Still, EYLEA HD posted a 54% increase in U.S. sales to $307 million, partially offsetting the decline. Dupixent remains a growth driver ...

Representative AI Generated Image After a buoyant start in March, fear has gripped summer product companies with sales of air-conditioners and refrigerators slipping sharply in April in some ...

Regeneron Pharmaceuticals ... a funding gap at copay assistance foundations. With respect to EYLEA, first quarter 2025 U.S. net sales were $736 million, down 39% compared to the first quarter ...

Starting in 2025, the Eylea franchise as a whole began to decline due to ... We assign Regeneron a Medium Morningstar Uncertainty Rating, as its future sales are well diversified with several ...

Regeneron reported quarterly revenue contraction of 4% year on year, which was largely driven by declines in its Eylea franchise. Original dose Eylea declined 39% year on year and 38% sequentially ...

The supplemental application is for the addition of extended dosing intervals (up to every 24 weeks) of EYLEA HD injection 8 mg across all approved indications. The FDA disagreed with Regeneron ...